CranioSense awarded $5.5M non-dilutive federal funding from NIH Blueprint MedTech and DoD for non-invasive ICP monitoring
Summary
CranioSense received $5.5M total from the NIH Blueprint MedTech Program and DoD JWMRP (Joint Warfighter Medical Research Program) for development of their non-invasive near-infrared ICP monitoring system. DoD called non-invasive ICP the "Holy Grail" of battlefield casualty care. Only 5% of TBI patients currently receive ICP testing due to invasiveness. Founded 2023.
Why it matters
Non-dilutive federal funding from both NIH and DoD for a 2023-founded company is exceptional validation — both agencies independently conducted merit review and concluded CranioSense's technology is both scientifically meritorious (NIH) and operationally critical (DoD). The dual-agency validation is a commercial credibility signal that far exceeds what a $5.5M venture investment would provide.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial